Targeting glutamine metabolism in PIK3CA mutant colorectal cancers

We recently reported that PIK3CA mutant colorectal cancers (CRCs) are addicted to glutamine through up-regulation of glutamate pyruvate transaminase 2 (GPT2). A GPT2 inhibitor suppresses in vivo growth of PIK3CA mutant, but not wild-type, CRCs. This study indicates that targeting glutamine may be an...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Xiujing, Hao, Yujun, Wang, Zhenghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153462/
https://www.ncbi.nlm.nih.gov/pubmed/30258894
http://dx.doi.org/10.1016/j.gendis.2016.09.001
Descripción
Sumario:We recently reported that PIK3CA mutant colorectal cancers (CRCs) are addicted to glutamine through up-regulation of glutamate pyruvate transaminase 2 (GPT2). A GPT2 inhibitor suppresses in vivo growth of PIK3CA mutant, but not wild-type, CRCs. This study indicates that targeting glutamine may be an effective approach to treat CRCs with PIK3CA mutations.

Ejemplares similares